The Cold Call and the 48-Hour Discount
A 180-bed community hospital's outpatient pharmacy is down to 44 vials of a generic injectable it uses at a steady 4 vials per day; the contracted wholesaler has the item on backorder with no release date. On Tuesday an unfamiliar secondary distributor cold-calls: 200 vials at $31 each versus the contract price of $47, "14-month dating," delivery within 48 hours. They offer to "send the DSCSA paperwork along with the driver." Their state wholesale distributor license number checks out as active, but they are not an authorized distributor of record for this manufacturer and are not on the hospital's GPO contract. The pharmacy manager is on vacation, and the buyer must decide by 5 p.m. today whether to order, how much to order, and on what conditions.
1. What must be established before this purchase can be placed at all, and what does the "paperwork rides with the driver" offer tell you?
Read the worked answer
Authority to buy is a gate, not a formality.
- Under DSCSA, a dispenser may acquire product only from an authorized trading partner. An active state license is necessary but not sufficient. Confirm the entity's licensure/registration and that it is authorized for this manufacturer's product. A cold call from an unknown entity that is not an authorized distributor of record is a classic diversion indicator.
- Transaction information, transaction history, and the transaction statement must be provided at the time of the transaction, in a form the pharmacy can read and retain. "It comes with the driver" means the pharmacy would take possession before it has the documentation. That is a refusal, not a negotiation point.
- Confirm serialized product identifier data can be supplied, and that the dating claim is verifiable from the lot/expiration on the TI, not from a sales rep's email.
- Contract check: if the molecule is on a GPO/committed-volume contract, an off-contract buy can jeopardize administrative fees or create a pricing-commitment problem. That requires the manager's or GPO's sign-off, not a buyer's.
If licensure, authorization, and the 3T cannot be confirmed before the order ships, the answer is no purchase - a shortage is a temporary cost; illegitimate product is an FDA-reportable event.
2. Size the deal: how many days of supply is 200 vials, what is the dollar exposure, and what quantity would you actually order?
Read the worked answer
Run the numbers before you run on price.
- 4 vials/day → 200 vials = 50 days of supply. Current stock 44 vials = 11 days.
- Exposure: 200 × $31 = $6,200 out of pocket versus 200 × $47 = $9,400 at contract, a nominal $3,200 "saving".
- But the $3,200 is only real if the product is legitimate, in date, and usable. With no authorized-distributor relationship, there is no practical recourse for a recall, a short-dated lot, or a failed verification - and no way to recover the cash.
- Sizing logic: buy to bridge the backorder, not to build a position. 10–15 days of cover (40–60 vials) limits exposure to roughly $1,200–$1,900 and rides out most backorders. Anything approaching 50 days of stock converts a supply problem into a financial and DSCSA-compliance problem.
- Because supply is short, also do the unglamorous work in parallel: ask the contracted wholesaler for an allocation date, check the manufacturer's direct/emergency order channel, and ask whether a sister hospital can transfer.
Judgment point: a deep discount from an unverified source during a shortage is the single most common profile in counterfeit/diverted-drug cases. Verify first, then buy small.
3. Regardless of the decision, what should be documented today, and what would trigger an FDA notification?
Read the worked answer
Document the decision, not just the purchase.
- Record the quote (price, quantity, dating), the license verification you performed and its date, the reason the supplier is or is not an authorized trading partner, and the clinical/contract rationale for the quantity chosen.
- If purchased: retain the TI/TH/TS with the receiving record, and record the product identifier data at receipt.
- If declined: a short note in the purchasing file ("offer declined - unverified ATP status, no 3T at time of transaction") protects the buyer and creates an audit trail.
FDA trigger: if any product from this supplier is later found to be suspect (tampered, counterfeit, wrong NDC/serial, no valid TI), quarantine it immediately, investigate, and once determined illegitimate, notify FDA (Form FDA 3911) and immediate trading partners within 24 hours, and keep the records of the investigation. Nothing from a suspect lot is dispensed or returned to stock while the investigation is open.